Errors in liver-made apolipoprotein B may damage blood vessels, muscles and glucose control
In naturally aging mice, correcting liver cells supplying half of apolipoprotein B (APOB) may improve vessel, muscle and glucose function. The mediator is rejected if benefit reflects lipid changes or persists after faulty APOB is restored; lifespan is tested separately.
Stage of verification
- Hypothesis published2026-09-30
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Specialised cell of an organ
Hepatocytes
Liver cells that produce and secrete proteins, including apolipoprotein B (APOB)
Where this hypothesis actsMature hepatocytes accounting for 50% of APOB production, excluding perivenous glutamine synthetase-expressing cells
Hypotheses on this target 1
Function restoration1
Reprogramming
Transplantation
Elimination
Proliferation
What is proposed
Function restoration
Improve protein synthesis accuracy in the selected hepatocytes
With whatGene delivery
HowTargeted genetic interventions; RPS23 K60R transfer first requires testing translation accuracy, synthesis speed and cell viability
Possible result
Possible improvements in vascular function, muscle strength, glucose tolerance and remaining lifespan
From the recordПовышение точности синтеза белка только в этом наборе должно уменьшить поступление повреждающих липопротеиновых частиц и увеличить оставшуюся продолжительность жизни.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
A mistake made in the liver could, in principle, carry damage to several other parts of the body. The unexpected move is to target cells responsible for half the liver’s production of apolipoprotein B, a protein that forms part of particles carrying fats through the blood, while holding the amount and fat composition of those particles comparable. This is a proposal generated by the pipeline, not a measured result.
- The proposal begins with liver cells inserting incorrect amino acids, the building blocks of proteins, into apolipoprotein B.
- The liver releases the erroneous protein in lipoproteins, particles that transport fats through blood.
- Particles carrying the erroneous protein are proposed to damage blood vessels, muscle recovery and blood-sugar regulation even at comparable particle numbers and fat composition.
- More accurate protein assembly in cells supplying 50% of production is predicted to reduce that damaging flow sufficiently; correction of 25% is predicted to leave enough to sustain harm.
- The reduced flow is predicted to improve all three functions, with a possible extension of remaining lifespan requiring a separate test.
A fleet of delivery trucks could damage several destinations because a structural part is faulty, even when the number of trucks and their loads stay the same. Replacing enough faulty parts might reduce damage without reducing deliveries.
Where the picture breaks: The proposal does not establish how the protein errors would cause damage, and biological particles do not behave like trucks. The picture also supplies no reason why correcting half the production would be sufficient.
- Master questionstep 01 of 04
Aging processes may reinforce one another, allowing an intervention at a shared cause to benefit several bodily systems.
Rests on: The goal takes the possibility of a shared, correctable cause as the basis for generating ideas that could extend life.
AssumptionThe existence of a shared cause whose correction would benefit several systems and extend life is a premise of the search, not an established finding in the supplied material.
- Goal pillarstep 02 of 04
The desired output is a collection of life-extension ideas that act through distinct causes.
Rests on: The master question explicitly requests ideas for interventions at shared causes of aging-related damage.
Stated in the chain - Gap questionstep 03 of 04
The search narrows to tissues, cell groups or distinct spaces within the body where correcting a shared cause could improve several systems and extend life. Reversing the proposed intermediary’s contribution is required to distinguish that explanation from competing targets.
Rests on: The preceding goal requires ideas that are causally distinct; targeted correction and reversal are introduced as the means of distinguishing them.
Stated in the chain - Hypothesisstep 04 of 04
Errors in assembling apolipoprotein B are proposed to make its fat-carrying particles damaging to blood vessels, skeletal muscles—the muscles that move the body—and blood-sugar regulation. Correcting protein assembly in mature liver cells responsible for 50% of its production is predicted to suffice, whereas 25% would not and 75% would add no further functional benefit. The target excludes cells near liver veins that make glutamine synthetase, an enzyme that incorporates ammonia into glutamine.
Rests on: The preceding question supplies the requirement for a specific cell group, a shared cause and a reversal test. The endpoint supplies the particular liver-protein mechanism as its proposed answer.
AssumptionThe specific causal role of protein-assembly errors, the choice of liver cells and the proposed production fractions are assumptions to be tested. Neither the preceding stages nor the screened sources establish those choices; being an untested proposal is not itself a missing logical step.
What is carried, and what is not. None of the three screened sources directly supports a causal link in the proposed error-to-damage-to-lifespan sequence. The Analyst paper from 2018 supplies an abstract reporting that a protein-measurement method was studied using fragments of apolipoprotein B and other proteins; it does not establish assembly errors, their effects or the proposed targeting fractions, and nothing supplied establishes the sequence end to end.
Where the reasoning is carried by something unstated · 2
- Master question. The existence of a shared cause whose correction would benefit several systems and extend life is a premise of the search, not an established finding in the supplied material.
- Hypothesis. The specific causal role of protein-assembly errors, the choice of liver cells and the proposed production fractions are assumptions to be tested. Neither the preceding stages nor the screened sources establish those choices; being an untested proposal is not itself a missing logical step.
How a result here could mislead · 3
- Loss of benefit after returning the original particles could be attributed to erroneous apolipoprotein B even if another difference between the returned preparations caused the harm. The proposal itself identifies isolating particles that differ specifically in these errors as its main technical limitation. What closes it: The returned preparations must have confirmed differences in protein-assembly errors while matching particle number and carried fats, as specified. Other relevant differences must be assessed before treating the reversal as specific evidence for the erroneous protein; the restored error burden must also be verified.
- A manipulation intended to improve protein accuracy could instead change protein-production speed or liver-cell survival. Either could change the released particles and obscure what caused a benefit or a failure. What closes it: Accuracy, production speed and cell survival must be measured in the targeted old liver cells, as the proposal requires. Changes in the errors carried by released apolipoprotein B must be established alongside particle number and fat composition.
- Treating half the liver cells could be mistaken for correcting half the protein production, or a weak comparison could be read as proof that 50% and 75% are equivalent. What closes it: Coverage must be measured as the share of apolipoprotein B production supplied by corrected cells, with the excluded cell group verified. Functional success criteria and the allowed difference defining equivalence must be fixed before testing; the supplied material provides no numerical criteria.
What would make this wrong. The proposed intermediary would be rejected if the benefits were explained by altered fat composition, or if benefits persisted after verified restoration of the original burden of erroneous apolipoprotein B. Verified correction of the intended production share without the predicted functional improvements would contradict the proposed sufficiency claim. Functional improvements without longer remaining life would leave the life-extension claim unsupported.
What it would change. If the predicted improvements and specific reversal held, erroneous liver-made apolipoprotein B would become a supported candidate for one shared cause of damage across several systems in naturally aging mice. Work on the master question would then need to distinguish protein-assembly quality from the amount and fat content of circulating particles, while checking that the competing ammonia-removal, hormone-timing and immune-cell-selection explanations had not changed. Functional improvement alone would still establish neither longer life nor benefit in humans, and the proposed 50% boundary would remain specific to the tested conditions.
Sources read · 3
Absolute two-point quantification of proteins using dimethylated proteotypic peptides. · The Analyst · 2018
“The method was studied with peptides of apolipoprotein A-I, apolipoprotein B-100, and leucine-rich alpha-2-glycoprotein without and with serum.”
Does not settle: This analytical-method abstract does not establish APOB amino-acid misincorporation, hepatocyte populations or production fractions, vascular, muscle, or glucose effects, particle number or lipid composition, or lifespan effects.
Atherosclerosis severity in patients with familial hypercholesterolemia: The role of T and B lymphocytes. · Atherosclerosis plus · 2022
“However, in multiple linear regression model, only CD4+T lymphocytes was independently associated with CAC.”
Does not settle: Источник не оценивает ошибки включения аминокислот в APOB, продукцию APOB отдельными наборами гепатоцитов, сопоставимость числа частиц и состава липидов, повреждение скелетных мышц или регуляцию глюкозы. Он также не проверяет пороги 25%, 50% или 75% и влияние повышения точности синтеза белка на продолжительность жизни.
Dietary sucrose induces metabolic inflammation and atherosclerotic cardiovascular diseases more than dietary fat in LDLr-/-ApoB100/100 mice. · Atherosclerosis · 2020
“We fed pro-atherogenic LDLr-/-ApoB 100/100 mice either a low-fat/high-sucrose (LFHS) or a high-fat/low-sucrose (HFLS) diet for 24 weeks.”
Does not settle: The source text does not establish amino-acid incorporation errors in APOB, liver-cell targeting or APOB production fractions, matched particle number or lipid composition, damage to vessels or skeletal muscle caused by erroneous APOB, or effects on lifespan.
The gap this hypothesis explains
Nothing is known here: the question has not been asked of this system.
Which tissue targets improve multiple systems and lifespan through a shared link rather than separate organ effects?
Original wording · exactly as the pipeline generated it
Какие ткани, клеточные популяции или компартменты содержат общие причинные звенья для самостоятельных идей «серебряных пуль», если адресная коррекция и обратное выключение посредника должны отличить их от конкурирующих мишеней по функциям нескольких систем и продолжительности жизни?
What this question is asking
The question asks where in the body a change could improve several bodily functions and extend life through one shared biological link. It seeks particular tissues, groups of cells, or distinct biological locations where targeted correction produces those benefits, and asks whether subsequently disabling the proposed mediator removes them. The comparison is with competing targets, including targets whose effects act separately on individual organs, using sustained function and lifespan over a common observation period. The question assumes that existing mapping and local interventions identify candidates but have not established a set of shared causal targets; the supplied sources establish only parts of that assumption.
- Tissue, cell population, and biological compartment
- A tissue is an organized part of the body made from cells; a cell population is a group of cells considered together. A compartment is a distinct biological location, such as a region within a cell or a body fluid, and the question asks where the proposed shared cause resides.
- Target and targeted correction
- A target is a biological component or process selected for change. Targeted correction means changing that component in the relevant location; calling it a correction does not establish that it produces a benefit.
- Shared causal target
- A component whose alteration causes effects in several body systems through a common link. A feature found in several tissues is only a candidate until its causal role is established.
- Mediator and mediator dependence
- A mediator is an intermediate part of the chain connecting an intervention to an outcome. Dependence means that the outcome requires that intermediate link; the question asks whether benefits are lost when the link is subsequently disabled.
- Multisystem function
- How well several body systems perform their jobs. Changes in several measured substances are not themselves evidence that several systems function better.
- Lifespan and healthspan
- Lifespan is how long an organism lives. Healthspan concerns time spent in good health or with preserved function, with the exact definition depending on how a study measures it.
- RL-1 and RL-2
- Labels used by the pipeline for levels of mapping and local intervention evidence. Their expansions and criteria are not supplied, so their evidential meaning cannot be established from this input.
- Gene activity
- The use of genetic instructions to make cellular products. S1 concerns regulation of this activity, while S7 measures the abundance of molecular instructions for particular proteins.
- Inflammation
- A set of immune responses involved in responding to damage or threats. Persistent inflammation is one of the processes discussed in the supplied accounts of fasting and communication between fat tissue and the brain.
- Caenorhabditis elegans and hypodermis
- Caenorhabditis elegans is the worm species studied in S2. Its hypodermis is an outer body tissue, compared with muscle in that source's imaging procedures.
- Mitophagy
- The process by which cells remove mitochondria, internal structures involved in energy production. S3 discusses its relationship with stress across ages and cell types rather than establishing a shared life-extending target.
- Ergothioneine
- A dietary antioxidant, meaning a substance associated with limiting certain damaging chemical reactions. S4 reports its increased abundance across tissues but does not establish that this increase causes the desired benefits.
- Plasma
- The fluid portion of blood. It is one of the locations where S4 reports increased ergothioneine.
- UM-HET3 mice
- The named mouse population studied in S4. The supplied results concern males from this population and do not establish the same effects in other populations or species.
- Preprint
- A research manuscript shared before formal journal peer review. S4 and S9 are identified as preprints in the supplied metadata.
- Brain's protective blood barrier
- The boundary that regulates movement of substances between the blood and brain tissue. S6 includes disruption of this boundary among the routes connecting disturbances in fat tissue to the aging brain.
- Heat shock proteins
- A class of proteins involved in helping other proteins maintain or recover their working form. S7 reports different patterns across members of this class and across tissues, so the term does not describe a single uniformly changing target.
- Long-lived dwarf mice
- The small-bodied, long-lived mice described in S7. Their longevity and tissue patterns are observations in that source, not proof that changing heat shock proteins accounts for their lifespan.
- Deoxyribonucleic acid (DNA) and cell-free DNA
- DNA is the molecule that carries genetic information. Cell-free DNA consists of DNA outside cells, including fragments circulating in blood; S8 does not establish which cells supplied the measured circulating material.
- LINE-1 methylation
- Long interspersed nuclear element-1, abbreviated LINE-1, is a class of repeated DNA sequences. Methylation is the attachment of small chemical marks to DNA, and S8 reports age-related loss of these marks at LINE-1 sequences without establishing that the loss causes aging.
- DNA polymerase alpha
- An enzyme involved in copying DNA. S9 concerns changes involving its gene, but the supplied evidence does not establish it as a shared target that extends lifespan.
- Fruit fly, cell lineage, and intestinal stem cells
- The fruit fly is the Drosophila organism studied in the quoted part of S9. A cell lineage comprises cells related through descent, while intestinal stem cells are cells capable of producing replacement cells in the gut.
- Regeneration
- Restoration of damaged or lost tissue. Better regeneration after a particular injury does not by itself demonstrate slower aging or longer lifespan.
- Gut microbial composition
- The makeup of the community of microorganisms living in the gut. S10 explicitly distinguishes changes in that community from demonstrated gains in healthspan.
Existing mapping and local interventions identify candidates but do not establish a set of shared causal targets with distinguishable dependencies, sustained benefits across several systems, and increased lifespan over a common observation period.
Mapping records where biological features occur, while local interventions change a particular tissue or group of cells. The assumption is that such work has produced possible targets without establishing which ones cause benefits across several systems and extend life. If that assumption holds, the unresolved task is distinguishing shared causes from changes that accompany aging or affect individual organs separately.
The supplied material supports the narrower statement that these sources identify tissue patterns and local effects without establishing the complete causal chain requested. S4 reports a shared chemical change across tissues, S8 reports an age-associated change in brain tissue and blood, and S9 reports regeneration and survival during recovery from injury. None of their supplied excerpts establishes the required shared target, mediator dependence, sustained multisystem function, and lifespan benefit together. This bounded source set does not establish that no other literature does so, and the input does not define its RL-1 and RL-2 evidence levels.S4S8S9
The same question asked without the part nothing read establishes:
- Which tissues, cell populations, or biological compartments have evidence that targeted correction improves several bodily functions and lifespan, with those benefits lost after the proposed mediator is disabled?
- What evidence distinguishes a shared causal target for improvements across body systems from separate effects on individual organs?
- A shared target produces the benefits Under the question's proposed mechanism, correcting the target would act through a common mediator to improve several systems and extend life. Losing those benefits when the mediator is disabled would support dependence on that link, while comparison with competing targets would determine whether the shared target offers the claimed advantage.
- Benefits arise through separate organ effects The change could improve different organs through different routes, so disabling one proposed mediator would not account for the whole pattern of benefits. A single shared target would then be an inadequate explanation, and the observed breadth of benefit would not establish that correcting one link reproduces it.
- Local benefits do not extend lifespan A targeted change could improve a tissue measurement or recovery from injury without producing sustained improvements across several systems. If lifespan does not also increase, that outcome would not meet the question's stated requirement for a shared life-extending target.
The proposed chain starts with a targeted change, passes through a mediator, and reaches the functions of several body systems before affecting lifespan. Similar changes in several tissues could identify a shared link, but those observations alone do not establish that the link produces the benefits. If separate organ effects were mistaken for one shared cause, correcting that supposed cause could fail to reproduce the expected breadth of benefit. Likewise, recovery after injury or a change in a measured biological feature does not by itself establish longer life.
Картирование и локальные вмешательства уровней RL-1 и RL-2 выделяют кандидатов, но экспериментального набора общих мишеней не устанавливают.
Установленный набор причинных мишеней с различимыми зависимостями, устойчивой функциональной пользой и положительным выигрышем продолжительности жизни за общий горизонт наблюдения.
Неизвестно, какие локализованные мишени действительно управляют несколькими системами и какие наблюдаемые эффекты объясняются прямым действием на отдельные органы.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Предлагаемый набор состоит из зрелых гепатоцитов, обеспечивающих50%продукции аполипопротеина B (APOB), с исключением перивенозных клеток, экспрессирующих глутаминсинтетазу. Гипотеза состоит в том, что ошибки включения аминокислот в секретируемый APOB создают общий источник повреждения сосудов, скелетных мышц и регуляции обмена глюкозы. Повышение точности синтеза белка только в этом наборе должно уменьшить поступление повреждающих липопротеиновых частиц и увеличить оставшуюся продолжительность жизни. Предполагается, что коррекции клеток, обеспечивающих четверть продукции APOB, недостаточно: оставшийся поток ошибочно синтезированного белка поддерживает повреждение. Доля50%является проверяемой границей в сравнении с25%и75%, а не установленным биологическим порогом. Причинным посредником служит ошибочно синтезированный APOB при сопоставимых количестве частиц и составе переносимых липидов.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
В естественно стареющих мышах коррекция указанной половины секреторной продукции улучшает сосудистую реактивность, восстановление мышечной силы и толерантность к глюкозе при сохранении исходных аммиачного профиля, гормональной пульсации и тимусной презентации антигенов. Коррекция четверти продукции не достигает заранее заданных функциональных границ, а увеличение охвата до75%даёт эквивалентный результат. Возврат выделенной из исходной плазмы фракции липопротеинов с подтверждёнными ошибками в APOB устраняет пользу; контрольная фракция с сопоставимыми липидами и числом частиц её сохраняет. Если эффект объясняется изменением липидного состава либо сохраняется после восстановления исходной нагрузки ошибочного APOB, предложенный посредник отвергается. Продление жизни проверяется отдельно.
Would tell it apart from at least one rival. The text predicts functional improvements, differing outcomes by correction coverage, and loss versus preservation of benefit after specified fraction returns. It also states explicit rejection conditions. No rival prediction is supplied. Lifespan extension is identified only as a separate investigation. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Репортёры точности трансляции, адресные генетические вмешательства в печени и анализ липопротеинов позволяют начать проверку. Выделение частиц, различающихся именно ошибками синтеза APOB, является главным техническим ограничением. Перенос варианта рибосомного белка RPS23 K60R в старые гепатоциты сначала требует проверки точности, скорости синтеза и жизнеспособности клеток; его полезность для млекопитающих здесь не предполагается установленной.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
В естественно стареющих мышах коррекция указанной половины секреторной продукции улучшает сосудистую реактивность, восстановление мышечной силы и толерантность к глюкозе при сохранении исходных аммиачного профиля, гормональной пульсации и тимусной презентации антигенов. Коррекция четверти продукции не достигает заранее заданных функциональных границ, а увеличение охвата до 75% даёт эквивалентный результат. Возврат выделенной из исходной плазмы фракции липопротеинов с подтверждёнными ошибками в APOB устраняет пользу; контрольная фракция с сопоставимыми липидами и числом частиц её сохраняет. Если эффект объясняется изменением липидного состава либо сохраняется после восстановления исходной нагрузки ошибочного APOB, предложенный посредник отвергается. Продление жизни проверяется отдельно.
- Rival 01 of 03What would separate them
Joint pituitary and adrenal correction may restore hormone pulses and improve multiple functions predicts: Только совместная коррекция двух популяций восстанавливает форму гормональных импульсов и улучшает три функциональные траектории. Коррекция одной популяции либо по 25% клеток каждой не достигает заранее заданной границы; увеличение охвата до 75% эквивалентно 50%. В отдельном опыте замена восстановленного импульсного профиля кортикостерона на исходный возрастной профиль при одинаковой суточной экспозиции устраняет удалённую пользу. Воспроизведение восстановленного профиля у контрольных старых мышей даёт функциональный эффект без коррекции печени или тимуса. Если достаточно одной популяции, гипотеза двухкомпонентного минимума отвергается.
- Rival 02 of 03What would separate them
Restoring ammonia capture near liver veins may preserve muscle and brain function and extend life predicts: После коррекции 80% перивенозных клеток уменьшаются постпрандиальные аммиачные пики, затем улучшаются восстановление мышечной силы и когнитивные показатели. Эти изменения возникают при сохранении исходных точности синтеза APOB, гормональной пульсации и тимусной презентации антигенов. Охват 40% проваливает функциональный критерий при сочетании пищевой и двигательной нагрузок; охват 100% эквивалентен 80%. Повторное выключение глутаминсинтетазы в скорректированных клетках либо восстановление исходного аммиачного профиля отменяет удалённую пользу. Если коррекция нормализует аммиак, но функции и выживаемость продолжают исходную траекторию, набор отвергается как «серебряная пуля».
- What would separate them
Loss of thymic self-antigen presentation may drive muscle and metabolic decline predicts: Совместная коррекция двух групп при охвате 80% снижает выход новых Т-лимфоцитов с подтверждённой реактивностью к выбранным собственным антигенам; спустя недели или месяцы улучшаются мышечное восстановление и регуляция глюкозы. Коррекция только мышечной группы даёт преимущественно мышечный эффект, только эндокринной группы даёт преимущественно метаболический эффект, а полный тимусный охват эквивалентен целевому набору. Повторное выключение презентации выбранных антигенов возобновляет появление соответствующих аутореактивных клеток и постепенно устраняет пользу. Немедленное улучшение за часы либо сохранение эффекта при восстановлении исходного выхода аутореактивных клеток противоречит этой гипотезе. Положительный функциональный результат должен сопровождаться отдельным подтверждением выигрыша выживаемости.
Why this is not the mainstream account
The engine is asked to say what its hypothesis would overturn and what would surprise a specialist. This is its answer.
Замена K60R в RPS23 повышала точность трансляции и увеличивала продолжительность жизни дрожжей, нематод и дрозофил; у исследованных нематод и дрозофил эффект точности удалось отделить от общего снижения трансляции. Это основание проверять ошибки синтеза как причинную переменную, но прямых данных об ошибочном APOB как системном посреднике работа не даёт. [Martinez-Miguel et al., 2021](https://pmc.ncbi.nlm.nih.gov/articles/PMC8570412/).
Биология липопротеинов и сосудистого старения. Пересмотра потребовал бы учебный раздел «Липопротеины и атерогенез»: при одинаковых количестве APOB-содержащих частиц и липидном составе главным различающим фактором общего возрастного повреждения оказалась бы точность синтеза их белкового компонента в ограниченном наборе гепатоцитов.
Коррекция точности синтеза только части печёночного секреторного белка продлевает жизнь старых мышей, хотя концентрации липопротеинов, липидный состав и собственная точность трансляции удалённых тканей остаются прежними; возврат ошибочного APOB избирательно отменяет многосистемную пользу.
Связь точности трансляции с долголетием уже обсуждается в литературе и сама по себе не является радикальной гипотезой. Радикальное утверждение здесь относится к достаточности ограниченного печёночного источника ошибочного APOB при фиксированных липидных показателях. В выполненном целевом поиске такого утверждения не найдено. Это ограниченная проверка новизны, которая не доказывает отсутствие всех соответствующих обзоров; статус HERETICAL остаётся предварительным.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
5 quantitative figures appear below and the hypothesis cites no study for any of them. They are the engine's own, and the marks in the text say which.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.